BEAM vs. ROIV, ASND, BPMC, BBIO, LNTH, RVMD, LEGN, ELAN, CYTK, and NUVL
Should you be buying Beam Therapeutics stock or one of its competitors? The main competitors of Beam Therapeutics include Roivant Sciences (ROIV), Ascendis Pharma A/S (ASND), Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Lantheus (LNTH), Revolution Medicines (RVMD), Legend Biotech (LEGN), Elanco Animal Health (ELAN), Cytokinetics (CYTK), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry.
Beam Therapeutics vs.
Beam Therapeutics (NASDAQ:BEAM) and Roivant Sciences (NASDAQ:ROIV) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations, valuation and community ranking.
Roivant Sciences has lower revenue, but higher earnings than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks.
99.7% of Beam Therapeutics shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 4.2% of Beam Therapeutics shares are owned by insiders. Comparatively, 7.9% of Roivant Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Beam Therapeutics received 5 more outperform votes than Roivant Sciences when rated by MarketBeat users. However, 77.27% of users gave Roivant Sciences an outperform vote while only 56.00% of users gave Beam Therapeutics an outperform vote.
Roivant Sciences has a net margin of 3,827.42% compared to Beam Therapeutics' net margin of -41.07%. Roivant Sciences' return on equity of -14.65% beat Beam Therapeutics' return on equity.
In the previous week, Beam Therapeutics had 10 more articles in the media than Roivant Sciences. MarketBeat recorded 16 mentions for Beam Therapeutics and 6 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.91 beat Beam Therapeutics' score of 0.60 indicating that Roivant Sciences is being referred to more favorably in the news media.
Beam Therapeutics has a beta of 1.92, indicating that its stock price is 92% more volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500.
Beam Therapeutics currently has a consensus target price of $47.67, indicating a potential upside of 74.73%. Roivant Sciences has a consensus target price of $17.93, indicating a potential upside of 57.68%. Given Beam Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Beam Therapeutics is more favorable than Roivant Sciences.
Summary
Beam Therapeutics beats Roivant Sciences on 10 of the 19 factors compared between the two stocks.
Get Beam Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BEAM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Beam Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:BEAM) was last updated on 1/31/2025 by MarketBeat.com Staff
Free BEAM Stock Alerts